Tonix Pharmaceuticals Validates TONMYA's Unique Pharmacokinetics in New Study — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals published clinical pharmacokinetic studies for TONMYA™ in the Journal Clinical Pharmacology in Drug Development on March 5, 2026.
The study confirmed that TONMYA's sublingual formulation achieves rapid transmucosal absorption and bypasses first-pass liver metabolism due to its proprietary basifying agent.
TONMYA demonstrated a 154% relative bioavailability compared to oral immediate-release cyclobenzaprine HCl, with reduced exposure to the active metabolite norcyclobenzaprine.
The studies showed that TONMYA is generally well tolerated, with mild or moderate adverse events such as oral hypoesthesia and abnormal taste.

The big picture

Tonix Pharmaceuticals' publication of clinical pharmacokinetic studies for TONMYA™ underscores its strategic focus on central nervous system (CNS) treatments. The study validates the company's proprietary sublingual formulation, which aims to improve the durability of analgesic response in fibromyalgia patients. This development comes at a time when there is significant unmet medical need in the treatment of chronic pain disorders, positioning Tonix Pharmaceuticals as a key player in the CNS therapeutics market.

What we're watching

Market Differentiation: Whether TONMYA's unique pharmacokinetic profile can sustain its market position as the first new FDA-approved treatment for fibromyalgia in over 15 years.
Regulatory Compliance: The pace at which Tonix Pharmaceuticals can navigate potential regulatory hurdles related to TONMYA's use during pregnancy and its interactions with other serotonergic drugs.
Commercialization Strategy: How Tonix Pharmaceuticals plans to leverage the study results to expand TONMYA's market reach beyond fibromyalgia into other indications like major depressive disorder and acute stress disorder.